miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). Recent evidence supports the role of microRNA-223 (miR-223) in modulati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Oncol
Egile Nagusiak: HAN, JING, ZHAO, FENGYI, ZHANG, JING, ZHU, HAIZHEN, MA, HU, LI, XUETAO, PENG, LINA, SUN, JIANGUO, CHEN, ZHENGTANG
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2016
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4809653/
https://ncbi.nlm.nih.gov/pubmed/26936292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2016.3401
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak